See more : The Japan Wool Textile Co., Ltd. (JWTXF) Income Statement Analysis – Financial Results
Complete financial analysis of Miromatrix Medical Inc. (MIRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Miromatrix Medical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SALA Corporation (2734.T) Income Statement Analysis – Financial Results
- YanGuFang International Group Co., Ltd. (YGFGF) Income Statement Analysis – Financial Results
- Nasdaq US Benchmark Reinsurance (SATCH.BO) Income Statement Analysis – Financial Results
- POET, LLC (PTBBU) Income Statement Analysis – Financial Results
- G.A. Holdings Limited (8126.HK) Income Statement Analysis – Financial Results
Miromatrix Medical Inc. (MIRO)
About Miromatrix Medical Inc.
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 953.47K | 33.07K | 46.53K | 250.00K |
| Cost of Revenue | 500.00K | 500.00K | 500.00K | 250.00K |
| Gross Profit | 453.47K | -466.93K | -453.47K | 0.00 |
| Gross Profit Ratio | 47.56% | -1,412.13% | -974.58% | 0.00% |
| Research & Development | 18.30M | 10.75M | 7.28M | 6.27M |
| General & Administrative | 8.72M | 4.64M | 2.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.72M | 4.64M | 2.11M | 2.44M |
| Other Expenses | 3.68M | 705.59K | -577.06K | -142.86K |
| Operating Expenses | 30.70M | 16.10M | 8.81M | 8.56M |
| Cost & Expenses | 31.20M | 16.60M | 9.31M | 8.81M |
| Interest Income | 333.47K | 1.97K | 8.73K | 106.43K |
| Interest Expense | 47.73K | 676.52K | 765.17K | 48.39K |
| Depreciation & Amortization | 333.47K | 171.37K | -1.19M | -142.56K |
| EBITDA | -29.91M | -16.79M | -11.45M | -9.13M |
| EBITDA Ratio | -3,137.20% | -50,771.66% | -24,598.53% | -3,653.69% |
| Operating Income | -30.25M | -16.96M | -10.26M | -8.99M |
| Operating Income Ratio | -3,172.17% | -51,289.94% | -22,047.17% | -3,596.67% |
| Total Other Income/Expenses | 404.43K | 2.29M | -51.02K | -535.08K |
| Income Before Tax | -29.96M | -14.67M | -10.31M | -9.53M |
| Income Before Tax Ratio | -3,142.21% | -44,368.10% | -22,156.82% | -3,810.70% |
| Income Tax Expense | 47.84K | 284.98K | -1.59M | -6.46M |
| Net Income | -30.01M | -14.96M | -8.72M | -3.07M |
| Net Income Ratio | -3,147.22% | -45,229.95% | -18,732.75% | -1,228.07% |
| EPS | -1.45 | -1.30 | -0.82 | -0.29 |
| EPS Diluted | -1.45 | -1.30 | -0.82 | -0.29 |
| Weighted Avg Shares Out | 20.73M | 11.48M | 10.57M | 10.48M |
| Weighted Avg Shares Out (Dil) | 20.73M | 11.48M | 10.57M | 10.48M |
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“Merger Sub”), has successfully...
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“Merger Sub”), a...
MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR)....
MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR)....
Shareholder Alert: Ademi LLP investigates whether Miromatrix Medical Inc. has obtained a Fair Price in its transaction with United Therapeutics
MILWAUKEE , Oct. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Miromatrix (Nasdaq: MIRO) for possible breaches of fiduciary duty and other violations of law in its transaction with United Therapeutics. Click here to learn how to join the action https://www.ademilaw.com/case/Miromatrix-inc-0 or...
Miromatrix Medical climbs 225% following $140m United Therapeutics bid
Shares in the artificial human organs specialist Miromatrix Medical Inc. jumped 25% in premarket trading following the announcement of its acquisition by United Therapeutics Corporation (NASDAQ:UTHR) for up to $140 million.
Why Is Miromatrix Medical (MIRO) Stock Up 235% Today?
Miromatrix Medical (NASDAQ: MIRO ) stock is rocketing higher on Monday after announcing an acquisition deal with United Therapeutics (NASDAQ: UTHR ). That deal has United Therapeutics agreeing to acquire Miromatrix Medical for $91 million in cash, which comes to $3.25 per...
MIRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Miromatrix Medical Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Miromatrix Medical Inc. (NASDAQ: MIRO) to United Therapeutics Corporation is fair to Miromatrix shareholders. Under the terms of the proposed transaction, United Therapeutics would...
Miromatrix Medical stock soars after it agrees to be bought by United Therapeutics
Miromatrix Medical Inc.'s stock MIRO, -2.80% jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. UTHR, -2.30% for $3.25 per share in cash, or about $91 million. The deal also includes...
United Therapeutics to Acquire Miromatrix Medical
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix.
Source: https://incomestatements.info
Category: Stock Reports